12 Drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues
-
Nirjhar Saha
Abstract
Drug repurposing is an alternative and effective strategy in drug discovery. Compared to the de novo drug discovery approach, drug repurposing is a rapid process to identify new uses of existing therapeutic entities for other newly emerging and existing diseases. Drug repurposing approach often relies on some commonalities in the biochemical pathways involved in the pathogenesis of the disease against which a particular drug has been approved and the pathogenesis of the new disease against which the repurposing of the existing drug is planned for. It has been recently observed that COX-2 expression, popularly known to be associated with the pathogenesis of inflammatory disorder causing arthritis, is increased in other pathophysiological conditions such as cancer, CNS disorders, respiratory disorders, diabetic peripheral neuropathy, and various microbial infections. These findings form the basis for considering the repurposing of COX-2 selective agents/drugs against these diseases. Thus, there have been reports on the uses of various selective COX-2 inhibitors for drug repurposing in the combination therapy regimen for the treatment of cancer, neuronal disorders, and microbial infections. Some clinical trials for the repurposing of COX-2 inhibitors are still in progress. This chapter deliberates on the recent developments in drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues.
Abstract
Drug repurposing is an alternative and effective strategy in drug discovery. Compared to the de novo drug discovery approach, drug repurposing is a rapid process to identify new uses of existing therapeutic entities for other newly emerging and existing diseases. Drug repurposing approach often relies on some commonalities in the biochemical pathways involved in the pathogenesis of the disease against which a particular drug has been approved and the pathogenesis of the new disease against which the repurposing of the existing drug is planned for. It has been recently observed that COX-2 expression, popularly known to be associated with the pathogenesis of inflammatory disorder causing arthritis, is increased in other pathophysiological conditions such as cancer, CNS disorders, respiratory disorders, diabetic peripheral neuropathy, and various microbial infections. These findings form the basis for considering the repurposing of COX-2 selective agents/drugs against these diseases. Thus, there have been reports on the uses of various selective COX-2 inhibitors for drug repurposing in the combination therapy regimen for the treatment of cancer, neuronal disorders, and microbial infections. Some clinical trials for the repurposing of COX-2 inhibitors are still in progress. This chapter deliberates on the recent developments in drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues.
Kapitel in diesem Buch
- Frontmatter I
- Preface V
- Contents VII
- List of authors IX
- 1 Contemporary trends in drug repurposing: Identifying new targets for existing drugs 1
- 2 Intellectual property and regulatory considerations in drug repurposing 23
- 3 Drug repurposing from an academic and industrial view 41
- 4 Implication of drug repurposing in the identification of drugs for neurological disorders 55
- 5 Implication of drug repurposing in the identification of drugs as antiviral agents 101
- 6 Implication of drug repurposing in the identification of antibacterial agents 115
- 7 The implication of drug repurposing in the identification of drugs for gastrointestinal disorders 139
- 8 Implication of drug repurposing in the identification of drugs for renal disorders 159
- 9 Drug repurposing strategy in the identification of drugs for cardiovascular disorders 181
- 10 Successful examples of blockbusters drugs for drug repurposing 207
- 11 Drug repurposing of drugs from natural and marine origins 221
- 12 Drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues 233
- 13 Advantages, opportunities, and challenges to drug repurposing 283
- Index 293
Kapitel in diesem Buch
- Frontmatter I
- Preface V
- Contents VII
- List of authors IX
- 1 Contemporary trends in drug repurposing: Identifying new targets for existing drugs 1
- 2 Intellectual property and regulatory considerations in drug repurposing 23
- 3 Drug repurposing from an academic and industrial view 41
- 4 Implication of drug repurposing in the identification of drugs for neurological disorders 55
- 5 Implication of drug repurposing in the identification of drugs as antiviral agents 101
- 6 Implication of drug repurposing in the identification of antibacterial agents 115
- 7 The implication of drug repurposing in the identification of drugs for gastrointestinal disorders 139
- 8 Implication of drug repurposing in the identification of drugs for renal disorders 159
- 9 Drug repurposing strategy in the identification of drugs for cardiovascular disorders 181
- 10 Successful examples of blockbusters drugs for drug repurposing 207
- 11 Drug repurposing of drugs from natural and marine origins 221
- 12 Drug repurposing of selective COX-2 inhibitors in the pursuit of new therapeutic avenues 233
- 13 Advantages, opportunities, and challenges to drug repurposing 283
- Index 293
